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Objective: To analyze and report the current data on the treatment of both
neurogenic and idiopathic detrusor overactivity with Botulinum toxin. Methods:
Literature review using Pub-Med and Medline from 1990 until June 30, 2006.
Results: Case series of patients with neurogenic detrusor dysfunction (NDD) and
idiopathic detrusor overactivity (IDO) range from 15 to 200 patients with follow
up from 12 to 36 weeks post-treatment. Significant improvements in cystometric
bladder capacity, reflex volume at first urge to void, and bladder compliance are
seen in nearly all patients. Approximately 50% of NDD patients achieved urinary
continence and almost all had improvement in bladder control up to 36 weeks
following treatment. Patients with IDO with urgency alone or with incontinence
also had urodynamic as well as symptom improvement. Approximately 75% of
patients with IDO and incontinence are dry at 12 weeks post-treatment. Urgency
disappears on average in two thirds of patients. Quality of life scores also shows
significant improvement for all groups. Conclusion: Botulinum toxin-A has
emerged as a promising option for the treatment of neurogenic and refractory
idiopathic detrusor overactivity. Studies to date have shown that not only is this
treatment effective at decreasing urinary symptoms and incontinence, as well as
improving potentially dangerous urodynamic measures, but it is also minimally
invasive, reversible and safe. Questions over proper dosing and dilution, number
of injection sites, and re-injection rates remain to be answered.
© 2006 International Federation of Gynecology and Obstetrics. Published by
Elsevier Ireland Ltd. All rights reserved.KEYWORDS
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International Federation of1. Background/Introduction
Botulinum toxin, first isolated in 1897, is synthesized
from the gram positive anaerobic bacteria, Clostri-
dium botulinum, and is the most potent naturallyGynecology and Obstetrics. Published by Elsevier Ireland Ltd.
306 N. Casanova et al.occurring neurotoxin known toman. This bacterium is
usually found in soil and can produce one of 7 distinct
toxins labeled A–G [1]. Currently the toxin subtypes A
and B have been clinically implicated in the treat-
ment of several neuromuscular conditions and have
been FDA approved in the treatment of blepharo-
spasm, strabismus, and wrinkles [2]. Currently use of
Botulinum toxin for neurogenic detrusor dysfunction
and idiopathic overactive bladder is off-label use of
this medication in the United States.
The toxin complex itself ranges from 300 to
900 kDa, which includes a 150 kD exotoxin, complete
with both a heavy and a light chain. This complex
exerts its action by heavy chain binding to a neuron,
leaving the light chain to cleave a specific site on the
target protein complex. Specifically, the light chain of
Botulinum toxin-A (BTX-A) cleaves the synaptosomal
associated SNAP-25 protein within the SNARE com-
plex, which is involved in the exocytosis of acetylcho-
line vesicles in peripheral motor neurons. Upon
execution of this cleavage, the motor neuron is
paralyzed, thereby inhibiting contraction and causing
muscle relaxation [3]. Overall, this chemodenervation
is fully reversible as the formation of functional
neuronal sprouts reconnects nerve endings in any-
where from 3 to 9 months on average [1]. In addition
to its reversibility, the response is both dose and site
specific, giving a safe and effective result.
Given the effect of Botulinum toxin on neuromus-
cular activity and both its reversibility and safety, the
interest in its therapeutic applications has grownover
the years to include indications such as juvenile
cerebral palsy, focal spasticity, cervical dystonia and
most importantly for this review, detrusor overactiv-
ity. In recent years preliminary data suggests that this
may be effective for both neurogenic (NDO) and
idiopathic detrusor overactivity (IDO) in decreasing
bladder pressures, frequency and incontinence epi-
sodes as well as increasing bladder capacity. This
discovery is quite important in that there is certainly
a need for alternative treatments for bladder
dysfunction. The side effects and effectiveness
profiles of current conservative measures, such
anticholinergic medications, plus the complications
associated with more definitive measures such as
bladder augmentation, encourage physicians and
scientists to seek new alternative therapies.
The procedure itself is usually performed under a
general or local anesthetic if bladder sensation is
intact. A 22F rigid cystoscope with a flexible 23 gauge
injection needle is then inserted into the bladder and
anywhere from 100 U to 300 U of Botulinum toxin
diluted in saline is injected in 15–30 different sites in
the bladder. The trigone is usually spared given its
extensive innervation and the risk of urinary retention.
The injections usually begin to take effect within 3–7 days and can last to an average of 6 months [3].
(Refer to http://www.med.umich.edu/lrc/pva/ for a
video of the procedure.)
The goal of this review is to analyze and report
the current data on the treatment of both neuro-
genic and idiopathic detrusor overactivity with
Botulinum toxin and to look at what the future of
this potentially revolutionary treatment holds.
2. Neurogenic detrusor overactivity
Involuntary detrusor contractions, as a result of
neurologic pathway interruption, are the hallmark of
the neurogenic bladder dysfunction [4]. As a result of
these uninhibited contractions, pressures in the
bladder can rise to dangerous levels, predisposing
patients to infection, causing incontinence and, if
severe, causing vesicoureteral reflux and renal dam-
age. Currently, anticholinergic medications, clean
intermittent catheterization and indwelling catheters
are used as conservative treatmentmeasures, but side
effects of the medications, complications related to
indwelling catheters and refractory symptoms are
often indications for more definitive measures. When
conservative measures fail, more invasive procedures
such as sacral root rhizotomy, pudendal nerve stimu-
lation, and bladder augmentation are usually the next
line of defense. However, these measures come with
quite a few complications of their own,making them a
less favorable option and leaving both physicians and
patients looking for alternative treatment methods.
Over the last few years, the use of Botulinum
toxin-A has been one of the front running contenders
in the search for amore suitable treatment. In a early
study reported in 2000 by Schurch et al. [5] (Table 1),
21 patients were evaluated at 6, 16, and 36 weeks
after either 200 or 300 U injections of BTX-A. At the
6 week follow up, 17 of the 19 patients evaluated
were fully continent and at 36 weeks, continence
persisted in 7 of the 11 remaining patients seen in
follow up, without significant complications. Inter-
estingly, the 2 patients who failed treatment and
continued to have incontinence at 6 weeks, received
only 200 U of the toxin vs. the higher 300 U dose. In
addition to symptomatic improvement, bladder
parameters on urodynamic testing improved in all
patients at all included time points. Mean cysto-
metric bladder capacity (MCBC) increased from
296.3 cc to 480.5 cc and 457.5 cc at 6 and 36 weeks
respectively as the mean reflex volume at first urge
to void (RV) also increased from 215.8 cc at baseline,
to 415.7 cc and 319.6 cc at 6 and 36 weeks. This study
also demonstrated increases in the mean bladder
compliance (MBC) and decreases in the mean
maximum detrusor pressure during uninhibited con-
tractions (MVP), which also persisted at 36 weeks.
Table 1 Outcomes of Botulinum toxin-A injection on neurogenic detrusor dysfunction
Study N= F/U Dose/inj # MCBC (cc) Reflex
volume (cc)
Continence/outcomes
Pre Post Pre Post
Schurch et al. [5] 21 36 weeks 200–300/20–30 296 457.5 215.8 319.6 –17/19 continent at 6 weeks
–7/11 continent at 36 weeks
–7 d/c meds, 10 dec by 20–50%
Bagi and Beiring-Sorenson [6] 15 6 weeks 300/30 350 457 13/15 cont, 2 reduced leak,
mean 7 mo cont
Reitz et al. [3] 200 36 weeks 300 U/30 272 352 236 291 –132/180 continent 12 weeks
–72/99 continent at 36 weeks
–45 d/c meds, and 118 reduced
medication use
Klaphajone et al. [7] 10 36 weeks 300 U/15–30 175 230 54 ∼70 –7/10 continent at 6 weeks
–5/10 continent at 36 weeks
Schurch et al. [8] 59 24 weeks a-300/30 a-293 a-398 a-255 a-305 I-QOL trial: all improved 50%
reduction in incont. ratesb-200/30 b-260 b-441 b-169 b-327
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above improvements, reporting continence in 13 of
their 15 study participants at 6 weeks post-injection.
Each patient's urodynamic parameters showed sig-
nificant changes, including decreases in their maxi-
mum detrusor pressures and significant increases in
their maximum volume at safe detrusor pressures of
b40 cmH2O (from a mean of 185 cc to 457 cc). These
results persisted at the 24 week follow up time.
The largest study was reported in 2004, and is
regarded as the current “gold standard”. Over 200
patients from different institutions across Europe
similarly demonstrated significant improvements in
both symptoms and urodynamic parameters in
patients with neurogenic bladder dysfunction treated
with BTX-A [3]. This study followed patients at 12 and
36 weeks after injection with 300 U of the toxin at 30
different injection sites. Of the 180 patients examined
at 12 weeks, 132 of them reported complete
continence, while the remaining 48 patients reported
significant improvement in their symptoms (73%
continence rate). At 36 weeks, 72/99 remaining
patients reported continence. Additionally, at
12 weeks, 45 patients were able to completely
discontinue their anticholinergic medications while
118 were able to significantly reduce their medication
use. Moreover, no significant complications were
noted as a result of the injections. From a urodynamic
standpoint, results were likewise quite impressive.
The mean MCBC increased significantly from a
baseline of 272 cc to 420 cc and 352 cc at 12 and
36weeks respectively. TheRV increased from236 cc to
387 cc and 291 cc at 12 and 36 weeks. And, much like
the Schurch study in 2000, this study also demonstrat-
ed significant beneficial changes in MVP and MBC
during follow up evaluations, overall supporting the
theory that BTX-A toxin may be quite beneficial in the
treatment of neurogenic detrusor dysfunction.Although many of the aforementioned studies did
show an overall increase in bladder compliance, none
of those papers specifically examined patients with
abnormally low compliance bladders. This special
population was studied by Klaphajone et al. [7] in
2005. This study evaluated the effects of 300 U BTX-A
injections in 10 patients with spinal cord injuries and
resultant abnormally low compliance bladders. Dur-
ing follow up evaluations, bladder compliance was
shown to increase significantly from 6.5 cc/cmH2O to
approximately 14.5ml/cmH2O at 6 and 16weekswith
a return closer to baseline at 36 weeks. Results were
similar for MCBC and RV as initial evaluations at
6 weeks showed ameanMCBC to increase from 175 cc
to 331 cc and RV from 54 cc to 86 cc. Again, these
results were maintained at 16 weeks but returned
close to baseline at 36 weeks.
While the results of these case series reported
above are quite encouraging for the use of BTX-A in
the treatment of neurogenic bladder overactivity,
the lack of controls and quality of life outcomes are
major limitations of these trials. One study, reported
in 2005 [8], however attempts to relieve these
limitations by creating a randomized controlled trial
to evaluate treatment. In this study a total of 59
matched patients were randomized into three groups
receiving 200 U BTX-A, 300 U BTX-A or placebo
injections and were evaluated at various time points
for a total of 24 weeks. Compared with placebo,
significant clinical and urodynamic improvements
were demonstrated in the 2 BTX-A groups. Among the
measured outcomes were incontinence episodes and
quality of life profiles using the validated I-QOL
questionnaire. Between the 2 BTX-A groups, there
was an overall continence rate of 50% with marked
improvement in I-QOL scores compared with placebo
at all evaluated time points (Fig. 1). MCBC and RValso
improved significantly in the BTX-A treatment groups
Figure 1 I-QOL scores in placebo vs. BTX-A treatment
groups. Data from this figure are taken from Ref. [9].
308 N. Casanova et al.citing increases inmeanMCBC from 293 cc at baseline
to 398 cc and RV from 255 cc to 305 cc. Much safer
maximumdetrusor pressures were also achievedwith
a decrease in MVP from an average of 92 cmH2O at
baseline, to 55 cmH2O at 24 weeks. There was no
statistical difference in efficacy between the two
BTX-A groups in outcome measures. Additionally this
treatment was deemed quite safe as no adverse
events were considered to be related to the study
medication. While this study clearly supports previ-
ous investigations, it is one of the only randomized
controlled trials examining this hypothesis, thus
lending strength to the overall data.
3. Idiopathic detrusor overactivity:
overactive bladder (OAB)
Overactive bladder syndrome (OAB) is defined as
urgency with or without urge incontinence that is
usually associated with frequency and nocturia. It is
usually idiopathic in origin and is a condition that
affects over 17% of the American and European
populations [9]. Much like neurogenic bladder dys-
function, this condition is characterized by frequentTable 2 Outcomes of Botulinum toxin-A injections on idio
Study N= T: f/u Dose/inj # MCBC (cc
Pre Po
Werner et al. [10] 26 36 weeks 100 U/30 216 34
Kuo [11] 20 24 weeks 200 U/40 325.1 37
Schulte-Baukloh
et al. [12]
7 24 weeks 300 U/40 224.4 30
Schmid et al. [9] 100 12 weeks 100 U/30 246 38uninhibited contractions of the bladder but due to
the intact ability to void with urge; this does not
usually result in dangerous pressure elevations within
the bladder [4]. The symptoms, however, create
quite an impact on patient quality of life and over the
past decade more and more patients have come
forward, looking for appropriate management. Cur-
rent management focuses on pharmacologic mea-
sures such as anticholinergic medications vs. invasive
surgical procedures to decrease symptoms. Given the
limitations of medical treatment such as a high side
effect profile and incomplete effectiveness, investi-
gators are searching for alternative measures. Since
preliminary data suggested that Botulinum toxin-A
may be effective in treating uninhibited neurogenic
bladder contractions, investigators postulated that
the toxin may be effective in treating idiopathic
bladder dysfunction as well. Studies now show that
in-fact, not only do the toxin injections decrease
symptoms, even in cases refractory to medications,
but they also improve urodynamic parameters. In a
study performed by Werner et al. in 2005 [10], 26
women with urge incontinence and urodynamic
evidence of detrusor overactivity were followed for
36weeks after injection of 100Uof BTX-A toxin. After
one week, patients were asked to decrease their use
of anticholinergic medications and subsequently,
voiding diaries and urodynamics were evaluated at
4, 12, and 36 weeks after injection. Overall,
improvements were demonstrated in urodynamic
parameters, urge symptoms, and quality of life. At
12 and 36 weeks respectively, the mean MCBC
increased from a baseline of 216 cc to 351.9 cc and
340.4 cc (Table 2) and the volume at first desire to
void increased from 116.8 cc to 192.2 cc and 171.4 cc
at 12 and 36 weeks. At 4 weeks, 18/26 (69%) of
patients reported continence and at 12 weeks, 16/20
were continent. However, at 36 weeks, only 1/5
remained continent. (All other patients were lost to
follow up.) Urge symptoms reportedly improved as
well, as the average daytime frequency decreased
from 11.7 episodes per day to 7.2 and 6.6 at 4 andpathic detrusor overactivity
) Volume @
first urge
to void (cc)
Continence/outcomes
st
0.4 116.8 171.4 16/20 continent at 12 weeks, small
sample size at 36 weeks
1.2 139.8 208.2 7/20 continent with improvement in 8
7.6 149 240 5/7: improved sx control
1 126 212 88% improvement in KHQ at 36 weeks:
still improvements but diminished vs.
16 weeks
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episodes per night to 1.2 at both 4 and 12 weeks.
Additionally, quality of life, as evaluated by the King's
Health Questionnaire (KHQ), significantly improved
at both 4 and 12 weeks, but statistical analyses were
not done at 36weeks due to the small sample size. No
serious complications or instances of urinary reten-
tion were reported, however 2 patients did develop
elevated PVRs at 4 weeks and were instructed to self-
catheterize for one week, or until the PVR was less
than 100. Overall, this study concluded that while
BTX-A seems to be both safe and effective in the
treatment of OAB, many questions, such as dosage,
number of injections and injection rate, remain
unanswered.
By looking at other studies, the question of dose
safety and efficacy may be informally addressed. A
study reported in 2005 by Kuo [11] evaluated 20
women with OAB after injection of 200 U of BTX-A
toxin vs. the 100 U used in the previous study. At the
12 and 24 week follow up times, mean MCBC
significantly increased from 224.4 cc to 314.9 cc
and 307.6 cc respectively and the volume at first
sensation to void increased from a baseline of
139.8 cc to 212 cc and 208.2 cc at 12 and 24 weeks.
Detrusor pressures also improved, showing pressure
decreases from29.8 cmH2O to 21.5 and 24.1 at 12 and
24 weeks respectively. Subjective efficacy was also
noted as continence at 12 weeks was achieved in 9 of
20 patients with 8 reporting improvement and at
24 weeks 7 remained continent and 8 continued to
report improvement. Although efficacy was certainly
demonstrated in this study, side effects such as
urinary retention and elevated PVRs were seen as
well. At 2 weeks, 6 patients demonstrated transient
urinary retention, 10 had elevated PVRs and 15
patients (75%) developed difficulty urinating and a
sensation of residual urine after voiding. Although the
majority of these adverse effects receded after
2 weeks, 6 patients continued to have PVRs of at
least 1/3 their total bladder capacity at 24 weeks.
Taken as a whole, this study does support the use of
BTX-A in the treatment of detrusor overactivity, but
suggests that in a population of patients with intact
bladder sensation, an elevated dose may cause tran-
sient urinary retention and elevated PVRs leading
researchers to believe that a lower dosemay bemore
appropriate.
In addition to its use in the treatment of detrusor
overactivity, BTX-A has also shown to be effective at
improving outcomes and satisfaction in patients with
overactive bladder symptoms without detrusor over-
activity. In a study performedby Schulte-Baukloh et al.
[12], 7 patients with overactive bladder symptoms
refractory to conservativemanagementwere injected
with 300 U of BTX-A and followed, evaluatingurodynamic parameters and subjective measures of
incontinence at 4, 12, and 24 weeks. Urodynamic
evaluation showed an increase in the volume at first
desire to void from 149 cc to 230 cc at 12 weeks and a
significant increase to 240 cc at 24 weeks. The MCBC
also increased significantly from 325.1 cc at baseline
to 391.2 cc at 12weeks and371.2 cc (not significant) at
24weeks. More important from the patient standpoint
were the decrease in frequency, nocturia, and the
overall control of their bladder symptoms. Frequency
decreased from9 to8.1 and7.4 timesperday at 12 and
24 weeks respectively and nocturia decreased from
1.9 to 1.0 and 1.5 times per night at 12 and 24 weeks.
Furthermore, 5/7 patients, through questionnaires,
reported improved urinary control while 6/7 stated
that they would undergo this treatment again. While
this paper does not include patients with detrusor
overactivity, it suggests that the BTX injections may
have even more applications in refractory urinary
symptoms than originally suggested.
Themost recent study, reported in July of 2006 by
Schmid et al. [9] in an ongoing prospective, non-
randomized trial evaluating 100 patients with over-
active bladder symptoms, with and without detrusor
instability after injection of 100 U BTX-A. At 4, 12,
and 36 weeks post-injection, these patients were
evaluated for urodynamic and quality of life para-
meters to determine both the effectiveness of this
treatment at this dose and effectiveness of the in-
jections in 2 subtypes of patients with refractory
symptoms (with and without detrusor instability). In
terms of quality of life as evaluated by the KHQ, 90%
of patients showed improvement in at least 1
category at both 4 and 12 weeks. This positive out-
come was also significant at 36 weeks, but was
slightly diminished given the reversibility of BTX-A.
Subjectively, 88% reported improvement in bladder
function, 80% of those who were incontinent were
dry and urgency disappeared in 66% of patients at
12 weeks. Additionally a significant decrease in
frequency and nocturia was noted throughout
patient types. In terms of urodynamics, a significant
correlation was found between clinically observed
symptoms and changes in urodynamic parameters.
Themean MCBC increased from 246 cc to 381 cc (56%
increase) at 12 weeks, the mean volume at first urge
to void increased from 126 cc to 212 cc and the MBC
increased from 24 to 41 cc/cmH2O. While these
values remained elevated a decline was noted at
36 weeks. Both daytime frequency and nocturia
were significantly reduced and persisted for the
three months (Table 3). No prolonged side effects
were noted; however 4 patients did develop
transient urinary retention with elevated PVRs,
requiring temporary ISC. This issue was resolved
with time and had little effect on symptomatic
Table 3 Urodynamic data after 100 U injections in
patients with OAB: clinical parameters
Parameter Mean
no.
preop
±SD
Mean no. postop±SD
1 month 3 months 9 months
No. pts 100 100 80 20
Daytime 13.5±0.6 7±0.8⁎ 7±0.8⁎ 8±2.4
310 N. Casanova et al.improvement. By and large, this study is well done
and sheds a bit of light on some of the more pressing
questions in the study of BTX in IDO. Overall it
suggests that 100 U dose injections are quite
effective in measures of both objective and subjec-
tive success and confirms that BTX-A is useful in both
patients with and without idiopathic detrusor
instability.frequency
Nocturia 4±0.25 1.6±0.3⁎ 1.6±0.3⁎ 2.1±0.9
⁎Statistically significant difference between pretreatment
and postoperative BTX-A treatment (ANOVA for repeated
measures with subsequent Bonferroni correction pN0.0001).
Data from this table are taken from Ref. [9].4. Head to head trial: BTX-A effectiveness
in neurogenic vs. idiopathic bladder
dysfunction
Although individually, BTX-A has been shown to be
effective in both neurogenic and idiopathic detrusor
overactivity, there are very few studies directly
comparing the efficacy in a mixed population. Popat
et al. in 2005 [13] studied 44 patients with NDO and
31 patients with IDO that had been injected with
300 U and 200 U of BTX-A respectively and evaluated
for urodynamics and subjective outcomes for a total
of 16 weeks. All patients reported improvement in
urinary control and approximately 63% of patients
reported continence at 16 weeks. Although it ini-
tially it seemed as if continence rates were better in
the NDO group at 4 weeks, no difference was shown
between the groups at 16 weeks, suggesting that
BTX-A is equally clinically effective in both patient
populations. Urodynamic evaluations were also
much improved in both groups at 16 weeks. The
mean MCBC in the IDO group increased from 193.6 cc
to 327.1 cc and increased from229.1 cc to 427.0 cc in
the NDO group, results that are significantly differ-
ent from baseline, but not significantly different
between groups. Results were similar for mean
bladder pressure, frequency and urge episodes.
Taken as a whole, this study both confirms previous
investigations implicating BTX-A as a treatment for
detrusor overactivity as well as reporting equivalent
efficacy in both patient populations.5. Botulinum toxin-B
In addition to the examination of Botulinum toxin-
type A in the management of detrusor overactivity,
Botulinum toxin-type B has also been investigated.
This subtype has a similar mechanism of action as the
A type, but cleaves a different target protein [1,15]
making it a potential therapeutic option for treat-
ment of patients unresponsive to toxin-type A or for
those patients who become resistant to repeated
toxin-A injections. The first urologic case using BTX-B
was reported by Dykstra et al. in 2003 [14]. In this
study, 15 patients with detrusor hyperreflexia weretreated with doses of BTX-B ranging from 2500 to
15,000 U. Outcomes were measured in terms of
subjective improvement in symptoms and upon
treatment, patients were found to have 5.27 fewer
frequency episodes per day. The longest duration of
the effect was 12 weeks, a result that highly
correlated with dose. A more extensive study
performed in 2005 examined the effect of 5000 U
BTX-B in 20 patients with neurogenic and idiopathic
detrusor overactivity vs. placebo with treatment
crossover after 6 weeks [15]. The primary outcome of
this study was average voiding volume, while the
secondary outcomes were frequency, incontinence
episodes, andQOLas evaluated by the KHQ. Across all
outcome measures, BTX-B was found to be signifi-
cantly superior to placebo, supporting earlier data
suggesting that BTX-B could be used for treatment of
detrusor overactivity in addition to BTX-A.
Another question, however, is whether BTX-B can
be used in cases refractory to or resistant to
repeated BTX-A injections. Resistance to BTX-A
has been reported and is postulated to be caused
by an antibody response to the specific toxin
subtype, resulting in a decreased response with
subsequent injections, eventually rendering this
treatment ineffective [15]. A case study performed
by Reitz et al. [16] in 2004 suggests that BTX-B may
be the answer to this problem. In this case report, 2
patients with neurogenic detrusor overactivity, who
became resistant to BTX-A injections after multiple
treatments were then treated with BTX-B. (Resis-
tance was measured by the extensor digitorum
brevis test in which motor potentials were mea-
sured before and after BTX-A injections.) In both
cases urodynamic and clinical outcomes after
7500 U of BTX-B showed benefits similar to those
demonstrated with BTX-A which lasted a mean of
5.5 months with no observed side effects. Addition-
al investigation is needed to increase the strength of
observation but this study lends optimism for the
use of BTX-B in BTX-A resistant patients.
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When considering new treatment options for any
disease process, cost benefit analysis is an impor-
tant component in determining the treatment's
widespread applications. In the case of BTX injec-
tions, it has been proven to be safe and effective in
the treatment of detrusor overactivity without
having to proceed to more invasive procedures,
but is the cost worth the results? It is estimated that
the cost of one intra-office treatment session of
BTX-A with intravesical anesthesia is ∼$1000 every
6 months. If compared to surgical management,
with the many thousands of dollars in costs accrued
in the OR and with subsequent follow up and
complications, BTX-A may be cost effective. How-
ever, since the FDA has not yet approved Botox for
the treatment of detrusor overactivity, insurance
companies seldom cover this cost, leaving many
physicians desperate to find ways to fund this
treatment to their patients. While this is unfortu-
nate, it is only with further research that BTX for
detrusor overactivity will become an FDA approved
application.
7. Conclusion
Current management of both idiopathic and neuro-
genic detrusor overactivity is focused on either
medical management with anticholinergic medica-
tions or more invasive measures such as bladder
augmentation and nerve stimulation to decrease
the debilitating symptoms of detrusor dysfunction.
However, when medical management fails and
surgery seems excessive, alternative treatment
options are needed. In the search for alternative
measures, Botulinum toxin-A has emerged as a
promising option. Studies to date have shown that
not only is this treatment effective at decreasing
urinary symptoms and incontinence, as well as
improving potentially dangerous urodynamic mea-
sures, but it is also minimally invasive, reversible
and safe. Questions over proper dosing and dilution,
injection sites, and re-injection rates remain to be
answered. Additionally, its short duration of action
(12–36 weeks), the proposed development of
resistance, as well as the possible need for general
anesthesia, makes its widespread use undefined at
this time. Current and ongoing studies are now
focusing on objective and subjective improvements
as well as the posed unanswered questions regard-
ing this treatment in a refractory patient popula-
tion. Although there still is work to be done, the
future of BTX-A use in management of detrusor
overactivity is hopeful.References
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